Leya F - Search Results

1

Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.

Walenga JM, Jeske WP, Wallis DE, Bakhos M, Lewis BE, Leya F, Fareed J. Walenga JM, et al. Among authors: leya f. Semin Thromb Hemost. 1999;25 Suppl 1:77-81. Semin Thromb Hemost. 1999. PMID: 10357156

2

Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty.

Fareed J, Walenga JM, Leya F, Bacher P, Hoppensteadt D, Messmore H, Pifarre R. Fareed J, et al. Among authors: leya f. Semin Thromb Hemost. 1991 Oct;17(4):455-70. doi: 10.1055/s-2007-1002655. Semin Thromb Hemost. 1991. PMID: 1803518 Review. No abstract available.

3

Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog.

Chamberlin JR, Lewis B, Leya F, Wallis D, Messmore H, Hoppensteadt D, Walenga JM, Moran S, Fareed J, McKiernan T. Chamberlin JR, et al. Among authors: leya f. Can J Cardiol. 1995 Jun;11(6):511-4. Can J Cardiol. 1995. PMID: 7780873

4

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG; Argatroban-915 Investigators. Lewis BE, et al. Among authors: leya f. Arch Intern Med. 2003 Aug 11-25;163(15):1849-56. doi: 10.1001/archinte.163.15.1849. Arch Intern Med. 2003. PMID: 12912723 Clinical Trial.

5

Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F; ARG-216/310/311 Study Investigators. Lewis BE, et al. Among authors: leya f. Catheter Cardiovasc Interv. 2002 Oct;57(2):177-84. doi: 10.1002/ccd.10276. Catheter Cardiovasc Interv. 2002. PMID: 12357516

6

Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.

Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Lewis BE, et al. Among authors: leya f. Chest. 2006 Jun;129(6):1407-16. doi: 10.1378/chest.129.6.1407. Chest. 2006. PMID: 16778256

7

Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period.

Lojewski B, Bacher P, Iqbal O, Walenga JM, Hoppensteadt D, Leya F, Fareed J. Lojewski B, et al. Among authors: leya f. Semin Thromb Hemost. 1995;21(2):228-39. doi: 10.1055/s-2007-1000398. Semin Thromb Hemost. 1995. PMID: 7660145

8

A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate model.

Bacher P, Iqbal O, Lojewski B, Walenga JM, Leya F, Fareed J. Bacher P, et al. Among authors: leya f. Thromb Res. 1993 May 15;70(4):295-306. doi: 10.1016/0049-3848(93)90102-t. Thromb Res. 1993. PMID: 8392758

9

Evaluation of hematologic alterations associated with daily administration of low molecular weight heparin (Mono-Embolex) for a 12-week period.

Lojewski B, Bacher P, Iqbal O, Walenga JM, Hoppensteadt DA, Leya F, Fareed J. Lojewski B, et al. Among authors: leya f. Semin Thromb Hemost. 1993;19 Suppl 1:36-43. Semin Thromb Hemost. 1993. PMID: 8395730

10

Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management.

Fareed J, Hoppensteadt DA, Leya F, Lewis B, Callas D, Wolf H, Bick RL. Fareed J, et al. Among authors: leya f. Clin Appl Thromb Hemost. 1999 Apr;5(2):78-91. doi: 10.1177/107602969900500203. Clin Appl Thromb Hemost. 1999. PMID: 10725987 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

102 results

Search Page

Filters